中国生物制药:默沙东与礼新合作进展正常

DoNews
15 Jul

7月15日,针对市场关于礼新与默沙东PD-1/VEGF双抗LM-299授权协议被“退货”的传言,中国生物制药回应称,合作正按许可协议有序推进。公司表示,目前技术转移正在进行中,完成后礼新将获得3亿美元里程碑付款。根据默沙东此前披露的信息,技术转移预计于2025年内完成。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10